欢迎来到淘文阁 - 分享文档赚钱的网站! | 帮助中心 好文档才是您的得力助手!
淘文阁 - 分享文档赚钱的网站
全部分类
  • 研究报告>
  • 管理文献>
  • 标准材料>
  • 技术资料>
  • 教育专区>
  • 应用文书>
  • 生活休闲>
  • 考试试题>
  • pptx模板>
  • 工商注册>
  • 期刊短文>
  • 图片设计>
  • ImageVerifierCode 换一换

    4S糖尿病亚组研究.ppt

    • 资源ID:67195845       资源大小:132.50KB        全文页数:17页
    • 资源格式: PPT        下载积分:16金币
    快捷下载 游客一键下载
    会员登录下载
    微信登录下载
    三方登录下载: 微信开放平台登录   QQ登录  
    二维码
    微信扫一扫登录
    下载资源需要16金币
    邮箱/手机:
    温馨提示:
    快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。
    如填写123,账号就是123,密码也是123。
    支付方式: 支付宝    微信支付   
    验证码:   换一换

     
    账号:
    密码:
    验证码:   换一换
      忘记密码?
        
    友情提示
    2、PDF文件下载后,可能会被浏览器默认打开,此种情况可以点击浏览器菜单,保存网页到桌面,就可以正常下载了。
    3、本站不支持迅雷下载,请使用电脑自带的IE浏览器,或者360浏览器、谷歌浏览器下载即可。
    4、本站资源下载后的文档和图纸-无水印,预览文档经过压缩,下载后原文更清晰。
    5、试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。

    4S糖尿病亚组研究.ppt

    Haffner SM,Alexander CM,Cook TJ,Boccuzzi SJ,Haffner SM,Alexander CM,Cook TJ,Boccuzzi SJ,Musliner TA,Pedersen TR,Kjekshus J,Pyorala K for Musliner TA,Pedersen TR,Kjekshus J,Pyorala K for the 4S Group the 4S Group Reduced Coronary Events in Simvastatin-Treated Subjects with CHD and Diabetes or Impaired Fasting Glucose:Subgroup Analyses in the Scandinavian Simvastatin Survival Study Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667Expanded 4S Diabetes AnalysisDiabetes Mellitus by HistoryDiabetes Mellitus by History 202 Subjects(Original 4S Diabetes Subgroup)202 Subjects(Original 4S Diabetes Subgroup)FG 126 mg/dl,but No History of DiabetesFG 126 mg/dl,but No History of Diabetes 281 Subjects281 SubjectsImpaired Fasting Glucose(FG 110-125 mg/dl)Impaired Fasting Glucose(FG 110-125 mg/dl)678 Subjects678 SubjectsNormal(FG 110 mg/dl)Normal(FG 126 mg/dl)126 mg/dl)New Category of IFG(FG 110-125 mg/dl)(FG 110-125 mg/dl)GoalsConfirm previous dataPerform analysis of 4S subjects with IFGHaffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667Baseline CharacteristicsNormalNormalIFGIFGDM-FGDM-FGDM-HxDM-Hxn n32373237678678281281202202AgeAge5959595959596060Male(%)Male(%)8080848489897878SBPSBP138138139139141141147147Tot-CTot-C261261261261261261259259LDL-CLDL-C189189189189186186189189HDL-CHDL-C4646454544444444TGTG130130137137142142153153FGFG9595117117136136175175Haffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667Percent Change in Lipids and Lipoproteins in 4SHaffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667Incidence of Major CHD Events by Glucose Status in the 4S Placebo GroupNFGNFG(n=1631)(n=1631)IFGIFG(n=335)(n=335)DM-FGDM-FG(n=135)(n=135)DM-historyDM-history(n=97)(n=97)Baseline Glucose StatusBaseline Glucose StatusHaffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-26674S Major Coronary Heart Disease EventsRR=RR=0.68 0.68 0.62 0.62 0.58 0.58p value=0.001p value=0.001 0.003 0.003 0.001 0.001n=n=1631/1606 1631/1606 335/343 232/251 335/343 232/251Haffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-26674S&RevascularizationsRR=RR=0.67 0.67 0.57 0.57 0.52 0.52p value=0.001p value=0.001 0.01 0.01 0.005 0.005n=n=1631/1606 1631/1606 335/343 232/251 335/343 232/251Haffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-26674S Total MortalityRR=RR=0.72 0.72 0.57 0.57 0.79 0.79p value=0.005p value=0.005 0.02 0.02 0.34 0.34n=n=1631/1606 1631/1606 335/343 232/251 335/343 232/251Haffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667IFG Subjects(n=678)IFG Subjects(n=678)0.00.00.20.20.40.40.60.60.80.81.01.01.21.21.41.4Relative RiskRelative RiskMCEMCERevascularizationRevascularizationTot MortalityTot MortalityCHD MortalityCHD Mortalityp=0.003p=0.003p=0.009p=0.009p=0.02p=0.02p=0.007p=0.0070.620.620.570.570.570.570.450.45Haffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667Diabetic Subjects(n=483)Diabetic Subjects(n=483)0.00.20.40.60.81.01.21.4Relative RiskMCERevascularizationTot MortalityCHD Mortalityp=0.001p=0.005p=0.34p=0.260.580.520.790.72Haffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667 Major CHD EventsMajor CHD EventsNFG SimvastatinNFG SimvastatinNFG PlaceboNFG PlaceboIFG SimvastatinIFG SimvastatinIFG PlaceboIFG PlaceboDM SimvastatinDM SimvastatinDM PlaceboDM PlaceboArch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667Effects of Simvastatin on Major Coronary Events by Glucose Status Stratified by Level of Lipid ParametersArch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667Absolute and Relative Risk Benefit of Simvastatin Therapy by Glucose Status for Major Coronary EventsNFGNFGIFGIFGDMDMSimvastatin group,No.(%)Simvastatin group,No.(%)299/1606(18.6)67/343(19.5)59/251(23.5)299/1606(18.6)67/343(19.5)59/251(23.5)Placebo group,No.(%)Placebo group,No.(%)428/1631(26.2)102/335(30.5)87/232(37.5)428/1631(26.2)102/335(30.5)87/232(37.5)Relative risk Relative risk 0.680.680.620.620.580.58P relative riskP relative risk0.0010.0010.0030.0030.0010.001Absolute benefit(Kaplan-Meier yearAbsolute benefit(Kaplan-Meier year 6 estimate)6 estimate)8.02/100 cases 12.11/100 cases 13.85/100 cases 8.02/100 cases 12.11/100 cases 13.85/100 casesNumber needed to treatNumber needed to treat12128 87 7Haffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667Summary-Diabetes MellitusSummary-Diabetes MellitusHigher event rate in diabetes group,by history,compared to other groupsIn combined DM group(by history and fasting glucose):Major Coronary Events were reduced by 42%(p=0.001)Revascularizations were reduced by 48%(p=0.005)Total and coronary mortality were reduced,but reductions not significant due to small sample sizeHaffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667Summary-Impaired Fasting GlucoseSummary-Impaired Fasting GlucoseReduced total mortality by 43%(p=0.02)Reduced coronary mortality by 55%(p=0.007)Reduced major coronary events by 38%(p=0.003)Reduced the need for revascularization procedures by 43%(p=0.009)Haffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667ConclusionsConclusionsThis analysis confirms and extends the benefit of cholesterol lowering with simvastatin in an expanded cohort of patients with diabetes and overt CHDCHD patients with impaired fasting glucose(FG 110 to 125 mg/dL)benefit from treatment with simvastatin by significant&substantial reductions in total and coronary mortality,major CHD events and revascularizations.Haffner SM,et al.Haffner SM,et al.Arch Intern MedArch Intern Med 1999;159:2661-2667 1999;159:2661-2667

    注意事项

    本文(4S糖尿病亚组研究.ppt)为本站会员(s****8)主动上传,淘文阁 - 分享文档赚钱的网站仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知淘文阁 - 分享文档赚钱的网站(点击联系客服),我们立即给予删除!

    温馨提示:如果因为网速或其他原因下载失败请重新下载,重复下载不扣分。




    关于淘文阁 - 版权申诉 - 用户使用规则 - 积分规则 - 联系我们

    本站为文档C TO C交易模式,本站只提供存储空间、用户上传的文档直接被用户下载,本站只是中间服务平台,本站所有文档下载所得的收益归上传人(含作者)所有。本站仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。若文档所含内容侵犯了您的版权或隐私,请立即通知淘文阁网,我们立即给予删除!客服QQ:136780468 微信:18945177775 电话:18904686070

    工信部备案号:黑ICP备15003705号 © 2020-2023 www.taowenge.com 淘文阁 

    收起
    展开